All In Biotech

Drug Trial Radar · NCT02637687

A Study to Test the Safety and Efficacy of the Drug Larotrectinib for the Treatment of Tumors With NTRK-fusion in Children

A Phase 1/2 Study of the Oral TRK Inhibitor Larotrectinib in Pediatric Patients With Advanced Solid or Primary Central Nervous System Tumors

Last checked: Nov 20, 2026Latest source record: Jun 22, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruiting

Status

Active, not recruiting

Enrollment

154

Actual

Start

Dec 16, 2015

Primary completion

Jul 20, 2024

Study completion Sep 30, 2026

Sponsor

Lead sponsor
BayerBayer (BAYRY)
Sponsor type
Industry
First posted
Dec 22, 2015

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Non randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
Who can join
All sexes, up to 21 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The study is being done to test the safety of a cancer drug called larotrectinib in children. The cancer must have a change in a particular gene (NTRK1, NTRK2 or NTRK3). Larotrectinib blocks the actions of these NTRK genes in cancer cells and can therefore be used to treat cancer. The first study part (Phase 1) is done to determine what dose level of larotrectinib is safe for children, how the drug is absorbed and changed by their bodies and how well the cancer responds to the drug. The main purpose of the second study part (Phase 2) is to investigate how well and how long different cancer types respond to the treatment with larotrectininb.

Conditions

  • Solid Tumors Harboring NTRK Fusion

Interventions

  • Larotrectinib (Vitrakvi, BAY2757556)Drug

    BAY2757556 will be administered orally as capsule or in liquid form over continuous 28-day cycles.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Phase 1: Number of participants in an assigned dose cohort with treatment emergent adverse events (TEAEs) by grade assessed by NCI-CTCAE v 4.03 who experience a DLTTime frame: From Day 1 to Day 28 of Cycle 1 (1 Cycle=28 days)
  2. Phase 1: Number of participants with TEAEsTime frame: From first dose of larotrectinib up to 93 months
  3. Phase 1: Severity of TEAEsTime frame: From first dose of larotrectinib up to 93 months
  4. Phase 2: Overall response rate (ORR) by IRRCTime frame: From first dose of Larotrectinib to disease progression or subsequent therapy or surgical intervention or death, up to 76 months

Locations

45 sites in 21 countries. Site status is shown where the registry gives one.

  • Children's Hospital Los Angeles - Hematology/Oncology

    Los Angeles, California

  • UCLA Jonsson Comprehensive Cancer Center

    Los Angeles, California

  • Lucille Packard Children's Hospital Stanford - Pediatric Nephrology

    Palo Alto, California

  • Nemours Children's Hospital - Florida - Hematology / Oncology

    Orlando, Florida

  • Dana-Farber Cancer Institute

    Boston, Massachusetts

  • Memorial Sloan Kettering Cancer Center New York - Main Campus

    New York, New York

  • Cincinnati Children's Hospital Medical Center | Division of Nephrology and Hypertension

    Cincinnati, Ohio

  • Children's Hospital of Philadelphia - Hematology/Oncology

    Philadelphia, Pennsylvania

  • St. Jude Children's Research Hospital

    Memphis, Tennessee

  • University of Texas Southwestern Medical Center

    Dallas, Texas

  • Seattle Children's Hosptial - Oncology

    Seattle, Washington

  • Sydney Children's Hospital

    Sydney, New South Wales, Australia

  • Women's and Children's Hospital

    North Adelaide, South Australia, Australia

  • Royal Children's Hospital Melbourne

    Parkville, Victoria, Australia

  • BC Children's Hospital - Hematology/Oncology

    Vancouver, British Columbia, Canada

  • The Hospital for Sick Children (SickKids)

    Toronto, Ontario, Canada

  • CHU Sainte-Justine

    Montreal, Quebec, Canada

  • Tianjin Medical University Cancer Institute & Hospital

    Tianjin, China

  • Beijing Children's Hospital, Capital Medical University

    Beijing, Beijing Municipality, China

  • Sun Yat-sen University Cancer Center

    Guangzhou, Guangdong, China

  • FN Brno - Detska nemocnice

    Brno, Czechia

  • Fakultni nemocnice v Motole

    Prague, Czechia

  • Rigshospitalet - Børn og Unge

    Copenhagen, Denmark

  • Institut Curie - Ulm - Paris

    Paris, France

  • Gustave Roussy - Departement Oncologie-Radiotherapie

    Villejuif, France

  • Charité - Campus Virchow-Klinikum (CVK), Klinik für Pädiatrie mit Schwerpunkt Onkologie und Hämatologie

    Berlin, Germany

  • Universitaetsklinikum Heidelberg - KiTZ | Klinik für Paediatrische Onkologie, Haematologie, Immunologie und Pneumologie

    Heidelberg, Baden-Wurttemberg, Germany

  • KLINIKUM STUTTGART - Olgahospital | Paediatrie 5 (Onkologie, Haematologie, Immunologie)

    Stuttgart, Baden-Wurttemberg, Germany

  • Children's Health Ireland Crumlin

    Crumlin, Dublin, Ireland

  • Clalit Health Services Schneider Children's Medical Center

    Petah Tikva, Israel

  • Fondazione IRCCS Istituto Nazionale dei Tumori - S. C. Pediatria Oncologica

    Milan, Lombardy, Italy

  • Kyushu University Hospital

    Fukuoka, Japan

  • Kanagawa Children's Medical Center

    Yokohama, Kanagawa, Japan

  • National Cancer Center Hospital

    Chuo-ku, Tokyo, Japan

  • Prinses Maxima Centrum

    Utrecht, Netherlands

  • Uniwersyteckie Centrum Kliniczne

    Gdansk, Poland

  • Severance Hospital, Yonsei University Health System

    Seoul, Seoul Teugbyeolsi, South Korea

  • Seoul National University Hospital

    Seoul, Seoul Teugbyeolsi, South Korea

  • Ciutat Sanitaria i Universitaria de la Vall d'Hebron

    Barcelona, Spain

  • Karolinska Universitetssjukhuset i Solna

    Stockholm, Sweden

Showing 40 of 45 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.